The U.S. Department of Health and Human Services has released "Revised Guidelines for HIV Counseling, Testing and Referral" and "U.S. Public Health Service Recommendations for HIV Screening of Pregnant Women," two draft documents for public comment.
The recommendations in "Revised guidelines for HIV Counseling, Testing and Referral" reflect the following findings:
•Â High-quality HIV prevention counseling models are effective in changing behaviors and reducing the incidence of sexually transmitted diseases in HIV-infected persons at increased risk.
•Â HIV treatment has been found to be effective in slowing the progression of HIV infection and improving the health of many HIV-infected persons, as well as the quality and duration of their lives.
•Â Therapy has been shown to dramatically reduce the risk of perinatal HIV transmission.
•Â New HIV testing technologies will simplify testing and allow for more availability of test results.
•Â New or updated guidelines on partner counseling and referral services, prevention case management, prevention and control of STDs, and prevention of opportunistic infections have been published.
"U.S. Public Health Service Recommendations for HIV Screening of Pregnant Women" has been updated to:
•Â Emphasize HIV testing as a routine part of prenatal care and strengthen the recommendation that all pregnant women be tested for HIV.
•Â Recommend a simplification of the testing process so that all previously required protest counseling is not a barrier to the provision of testing.
•Â Make the consent process more flexible to allow for various types of informed consent.
•Â Recommend that providers explore and address reasons for refusal of testing.
•Â Place more emphasis on HIV testing and treatment at the time of delivery for women who have not received prenatal testing and chemoprophylaxis.
Copies of the documents are posted on the Division of HIV/AIDS Prevention Web site at www.cdc.gov/hiv. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.